<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00797069</url>
  </required_header>
  <id_info>
    <org_study_id>BK20</org_study_id>
    <nct_id>NCT00797069</nct_id>
  </id_info>
  <brief_title>Comparison of Nutritional Products for People With Type 2 Diabetes</brief_title>
  <official_title>Comparison of Nutritional Products for People With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Nutrition</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Nutrition</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the glycemic and insulinemic responses of a standard nutritional product with two
      diabetes-specific nutritional products in patients with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the postprandial glycemic response of patients with type 2 diabetes consuming single servings of a standard liquid nutrition product and two diabetes-specific liquid nutrition products.</measure>
    <time_frame>Three crossover periods</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the postprandial insulinemic response of patients with type 2 diabetes consuming single servings of a standard liquid nutrition product and two diabetes-specific liquid nutrition products.</measure>
    <time_frame>Three crossover periods</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>standard nutritional product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard nutritional product not specific for diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>diabetes specific product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diabetes specific nutritional product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental diabetes specific product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diabetes specific experimental nutritional product</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard nutritional product (medical food)</intervention_name>
    <description>once during crossover</description>
    <arm_group_label>standard nutritional product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>nutritional product for diabetes (medical food)</intervention_name>
    <description>once during crossover</description>
    <arm_group_label>diabetes specific product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diabetes specific experimental nutritional product (medical food)</intervention_name>
    <description>once during crossover</description>
    <arm_group_label>Experimental diabetes specific product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject states that he/she has type 2 diabetes (as evidenced by use of oral
             hypoglycemic medication for at least two months).

          2. Subject is between 18 and 75 years of age, inclusive.

          3. Subject is a male or a non-pregnant, non-lactating female, at least 6 weeks postpartum
             prior to screening visit.

          4. If female is of childbearing potential, is practicing a method of birth control.

          5. Subject's BMI is &gt; 18.5 kg/m2 and &lt; 35 kg/m2.

          6. If on a chronic medication such as anti-hypertensive, lipid-lowering, thyroid
             medication or hormone therapy, subject has been on constant dosage for at least two
             months prior to screening visit.

        Exclusion Criteria:

          1. Subject uses exogenous insulin for glucose control.

          2. Subject states that he/she has type 1 diabetes.

          3. Subject states that he/she has a history of diabetic ketoacidosis.

          4. Subject takes an alpha-glucosidase inhibitor.

          5. Subject states that he/she has a current infection ; has had inpatient surgery, or
             corticosteroid treatment in the last 3 months or antibiotics in the last 3 weeks prior
             to screening visit.

          6. Subject states that he/she has an active malignancy (excluding the following dermal
             malignancies: basal cell carcinoma, squamous cell carcinoma, carcinoma in-situ of the
             cervix).

          7. Subject states that he/she has had a significant cardiovascular event â‰¤ six months
             prior to screening visit; or stated history of congestive heart failure.

          8. Subject states that he/she has end stage organ failure or is status post organ
             transplant.

          9. Subject states that he/she has a history of renal disease.

         10. Subject states that he/she has current hepatic disease.

         11. Subject states that he/she has a history of severe gastroparesis.

         12. Subject states that he/she has a chronic, contagious, infectious disease, such as
             active tuberculosis, Hepatitis B or C, or HIV.

         13. Subject has taken/is currently taking any herbals, dietary supplements, or
             medications, other than oral hypoglycemic medications, during the past four weeks
             prior to screening visit that could profoundly affect blood glucose.

         14. Subject states that he/she has clotting or bleeding disorders.

         15. Subject is known to be allergic or intolerant to any ingredient found in the study
             products.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Williams, MS</last_name>
    <role>Study Chair</role>
    <affiliation>Abbott Nutrition</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2008</study_first_submitted>
  <study_first_submitted_qc>November 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2008</study_first_posted>
  <last_update_submitted>July 29, 2010</last_update_submitted>
  <last_update_submitted_qc>July 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Bobbie Swearengin, Director Clinical Research</name_title>
    <organization>Abbott Nutrition</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

